



**Funded by the
European Union**

UNDINE

Project number:	101057100
Project name:	The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalised medicine
Topic:	HORIZON-HLTH-2021-DISEASE-04-07
Type of action:	HORIZON Research and Innovation Actions (RIA)
Starting date of action:	1 June 2022
Project duration:	48 months
Project end date:	31 May 2026
Deliverable number:	D8.7
Deliverable title:	Postdoc projects completed
Document version:	Ver1.0
WP number:	WP8
Lead beneficiary:	AU
Main author(s):	André Walter (AU), Trine Mogensen (AU)
Internal reviewer(s):	Mette Presser (AU)
Nature of deliverable:	OTHER
Dissemination level:	PU
Delivery date from Annex 1:	M36
Actual delivery date:	M38

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.

Executive Summary

Several work packages of the UNDINE-project rely on the research of postdoctoral scientists in support of the PIs within the consortium. The extensive work programme would not be feasible without their contribution. This Deliverable reports on the status of their individual progress and the completion of their work. As of Month 36, we expected most of the postdoc projects being finished or close to the end. However, as described below some of them will be continuing until the end of the UNDINE programme, as more postdoc support is still required. The contribution of the postdocs further boosted the communication and dissemination activities of UNDINE significantly, and we here also report on the status of those activities consortium-wide. The summary given in this Deliverable further marks the reaching of Milestone 8.4.

Abbreviations

AU	Aarhus University
D	Deliverable
DEP	Dissemination and Exploitation of Results plan
PI	Principal Investigator
PM	Person Months
1 st PR	First Periodic Report
WP	Work package

Contents

1	Postdoc projects.....	3
2	Status and verification of publication and communication output	4
2.1	<i>Publication list of the UNDINE project until Month 38</i>	6
3	Conclusions	10

List of Tables

Table 1.	End dates of postdoc projects with the UNDINE work programme	3
Table 2.	Summary of Communication activities of the UNDINE consortium until Month 38	5
Table 3.	Summary of Dissemination activities of the UNDINE consortium until Month 38	6

List of Figures

Figure 1.	Cover of the UNDINE information-flyer	4
-----------	---	---

1 Postdoc projects

One of the early tasks to establish a functioning research environment for UNDINE's ambitious work programme was the recruitment of qualified postdocs for the 7 research work packages, with excellence as a major criterion and an equal gender and diversity balance as the prerequisite. This task was initially planned to be completed in Month 4 but experienced a delay due to various reasons (cf. 1st PR). An amendment of the original project plan and a delay of handing in of financial identification forms (FIF) by some beneficiaries prevented a swifter recruitment. Some partners within the UNDINE-consortium were able to employ their postdocs as early as Month 5 (e.g., AU), while others were not able to do that before Month 10. At the end of the first reporting period (Month 18), all work packages that had planned to employ postdocs for the conduction of their experiments had done so.

Depending on the number of applied person months (PM) and the national salary level of the participating partner organisation, the duration of individual postdoc-projects varied greatly across the consortium. Other factors determining the duration of postdoc projects is the temporary suspension of project experiments, or their late start, due to the interdependence with the progress of other WPs and partner labs and potential waiting times for the provision of required base data. Thus, in month 36 some of the postdoc projects have been completed, while others will end soon, or even only at the end of Month 48. Table 1 presents an overview of the end dates of all postdoc projects within UNDINE for both past and future terminations.

Table 1. End dates of postdoc projects with the UNDINE work programme.

<i>partner ID</i>	<i>postdoc no.</i>	<i>mont postdoc project ended/ ends</i>
VHIR	Postdoc 1	10
SERMAS	Postdoc 1	19
UNITOV	Postdoc 1	20
OSR	Postdoc 1	20
DPZ	Postdoc 1	33
VHIR	Postdoc 2	34
OSR	Postdoc 2	36
AU	Postdoc 1	37
AU	Postdoc 2	41
TCD	Postdoc 1	41
KU Leuven	Postdoc 1	46
IP	Postdoc 1	48
IGTP	Postdoc 1	48
UMCU	Postdoc 1	48
UTARTU	Postdoc 1	48

2 Status and verification of publication and communication output

The UNDINE project aims at a "bed side to bench" and "bench to bed side" approach and thus meets a broad spectrum of audiences interested in its research activities and their outcome. Accordingly, the project addresses: I) the scientific community (researchers), II) the medical community (clinicians), III) patients, IV) medical students and PhD students within infectious diseases, virology, immunology and microbiology research areas V) the general public, VI) the pharmaceutical industry, and VII) regulators and health care providers. Our communications as well as our dissemination and results exploitation strategy is described in detail in our DEP, submitted as Deliverable 8.4 in Month 6. The various measures outlined there are taken to optimally reach out to our target audiences and to maximise the project's impact.

During the first reporting period, we started out with the creation of a project logo as a visual identity to support a coherent and recognizable communication among beneficiaries, associated partners, participating hospitals, paraclinical departments and research labs, as well as the general public. We since are using this logo for labelling document templates, power-point slides, our homepage, social media appearances and print products.

The UNDINE consortium has later created a flyer, a paper-folder, that communicates the objectives of the project, the methods that are used to reach its goals and about the structure and partners involved (Fig 1). All beneficiaries are free to replicate and print this flyer for individual distribution. This includes the posting of it on black boards, leaving it as information material in meeting rooms and bringing it to various conferences. The aim of this activity has been to increase the awareness of the project among the general public as well as the scientific community and to facilitate the extension of the network for future collaborations.



Figure 1. Cover of the UNDINE information-flyer (3-page folder), which informs about the project aims, its structure and the involved partners in the consortium.

Apart from that, main measures of communication have been official press releases and interviews informing about the project's purpose and progression as well as public information events. Dissemination activities of UNDINE's results have been taking place in form of conference attendances with oral and poster presentations as well as numerous scientific publications. A comprehensive list of UNDINE's communication and dissemination activities is found in the below tables (Tab 3 & Tab 4). Moreover, a complete up-to-date publication list is added below (2.1).

After the termination of most of the postdoc projects, the mentioned activities may slow down due to the reduction of the engaged personnel yet are not ending at the time of submission of this Deliverable. More results are still expected for the remaining project year and will still be communicated and distributed as outlined in the DEP. An overview of all activities will be available at all times on the UNDINE-homepage (<https://biomed.au.dk/undine/outreach> and <https://biomed.au.dk/undine/publications>). The same web-page is also listing all public Deliverables, which can be downloaded from there.

Table 2. Summary of Communication activities of the UNDINE consortium until Month 38.

no.	partner ID	month	type	details/comments
1	AU	1	Press release at AU	Title of article: "Major grant: Aarhus helping to answer the big coronavirus questions"
2	UMCU	1	Interview for a journal	interview for an article in the "Washington Post"
3	AU	8	Interview for a journal	"EUindblik", a journal of the Danish Ministry of Higher Education & Science
4	KU Leuven	15	Interview for a journal	"HUMO", public online journal
5	TCD	16	Public lecture	EU Researchers Night
6	VHIR	17	Press release at VHIR	Title of the article: "The UNDINE project on the determinants of COVID-19"
7	AU	18	Interview for a journal	"Berlingske", a Danish Newspaper
8	UTARTU	23	Public lecture	Public event in Biomedicum (UTARTU): "International Day of Immunology"
9	UTARTU	24	Symposium	European Federation of Immunological Societies and Baltic Societies of Immunology: "Immunology research and EU funded projects in Estonia" Vilnius/Lithuania
10	UNITOV	26	Interview for a journal	"Quotidiano Sanità", an Italian health communication journal
11	UNITOV	27	Interview for a journal	"Quotidiano Sanità", a newspaper in the Italian healthcare sector
12	TCD	28	Public lecture	EU Researchers Night
13	INSERM	29	Youtube interview	youtube-channel of Ludovic B (@LudovicBvideos)
14	INSERM	33	Award speech	J.L. Casanova (INSERM) receiving the 2025 Novo Nordisk Prize
15	KU Leuven	33	Public lecture	"600 second lecture at KU Leuven 600 years' celebration", title: "Bad infection: it may be in your genes"
16	UTARTU	34	Public lecture	Public event in Biomedicum (UTARTU): "International Day of Immunology"
17	KU Leuven	34	Interview for a journal	"DeMorgen", a Belgian news journal
18	AU	36	Article in a public journal	"Podvact for Ugeskrift for læger" (Danish Medical Bulletin) - title: "CRISPR gene editing to cure primary immunodeficiencies"

Table 3. Summary of Dissemination activities of the UNDINE consortium until Month 38.

no.	partner ID	month	type	event details/comments
1	bioMérieux	10	Poster presentation	"Cell Symposium: Viruses in health and disease", Sitges/Spain
2	IGTP	19	Oral presentation	"Demystifying Long-Covid - Intern. Conference 2023", Madrid/Spain
3	IP	20	Oral presentation	"12th Human and Medical Genetics Symposium", Paris/France
4	UNITOV	21	Oral presentation	Seminar at the University of Trieste/Italy
5	IGTP	22	Poster presentation	"Conference on Retroviruses and Opportunistic Infections (CROI)", Denver/USA
6	UTARTU	22	Oral presentation	"Formosa Translational Immunology Symposium", Taipei/Taiwan
7	IP	22	Oral presentation	keynote lecture at "Keystone Symposia on Molecular and Cellular Biology", Keystone/USA
8	UNITOV	23	Poster presentation	"Human Genome Meeting (HGM)", Rome/Italy
9	IGTP	24	Oral presentation	"Campus Can Ruti PhD Day", Badalona/Spain
10	UTARTU	24	Oral presentation	"Baltic-Polish School of Immunology 2024", Bialystock/Poland
11	IP	24	Oral presentation	"Human Immunology - Genes and Environment", Hinxton/UK
12	IP	27	Oral presentation	Seminar at Icahn School of Medicine, Mount Sinai, New York/ USA
13	IP	27	Oral presentation	Seminar at the New York Genome Center, New York/USA
14	IP	27	Oral presentation	Seminar at Rockefeller University, New York/USA
15	UNITOV	29	Oral presentation	"Health Extended Alliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches of Precision Medicine Meeting", Palermo/Italy
16	IGTP	30	Oral presentation	"Demystifying Long-Covid - Intern. Conference 2024", Barcelona/Spain
17	UNITOV	30	Oral presentation	"Workshop della Spienza", Rome/Italy
18	UTARTU	30	Oral presentation	"Seminar of the Estonian Society for Immunology and Allergology", Viljandi/Estonia
18	IP	31	Oral presentation	"11th HKU-Pasteur Immunology Course", Hong Kong/China
19	IP	32	Oral presentation	keynote lecture at "Annual Day of Microb'UP Institute", Paris/France
20	IGTP	34	Oral presentation	"Conference on Retroviruses and Opportunistic Infections (CROI)", San Francisco/USA
21	UNITOV	35	Oral presentation	"Human Genome Meeting (HGM)", Durban/South Africa
22	IGTP	36	Oral presentation	"R2P meeting on Post-COVID-19 Condition", European Commission
23	UTARTU	36	Oral presentation	"Baltic-Polish School of Immunology 2025", Vilnius/Lithuania

2.1 Publication list of the UNDINE project until Month 38

2025

- Rapid Detection of Anti-IFN- α 2 Autoantibodies Using a New Automated VIDAS Assay Prototype.** Pons S, Generenaz L, Gervais A, ... Bastard P, ... Casanova JL, Fleurie A, Trouillet-Assant S. *Eur J Immunol.* 2025 Apr;55(4):e202451516. doi: 10.1002/eji.202451516. PMID: 40223598.
- Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains.** Saidoune F, ... Fellay J, Casanova JL, ... Yatim A. *J Exp Med.* 2025 Jul 7;222(7):e20231467. doi: 10.1084/jem.20231467. Epub 2025 Apr 14. PMID: 40227192.
- Genetic Landscape and Mitochondrial Metabolic Dysregulation in Patients Suffering From Severe Long COVID.** Hansen KS, Jørgensen SE, Cömert C, ... Mogensen TH. *J Med Virol.* 2025 Mar;97(3):e70275. doi: 10.1002/jmv.70275. PMID: 40025839.
- Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D.** Arora P, Zhang L, Nehlmeier I, ... Pöhlmann S. *J Virol.* 2025 Feb 25;99(2):e0123024. doi: 10.1128/jvi.01230-24. PMID: 39791910.
- Severe West Nile Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Infections in a Patient With Thymoma and Anti-Type I Interferon Antibodies.** Barzaghi F, Visconti C, Pipitone GB, ... Bastard P, ... Casanova JL, ... Casari G, Aiuti A. *J Infect Dis.* 2025 Feb 4;231(1):e206-e212. doi: 10.1093/infdis/jiae321. PMID: 38976510.
- A common form of dominant human IFNAR1 deficiency impairs IFN- α and - ω but not IFN- β -dependent immunity.** Al Qureshah F, Le Pen J, ... Abel L, Bastard P, ... Zhang SY, ... Casanova JL, Zhang Q. *J Exp Med.* 2025 Feb 3;222(2):e20241413. doi: 10.1084/jem.20241413. PMID: 39680367.
- Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1.** Zhang L, Kempf A, Nehlmeier I, ... Pöhlmann S. *Lancet Infect Dis.* 2025 Feb 25. doi: 10.1016/S1473-3099(25)00113-6.

8. **Genetic diversity of the immunoglobulin heavy chain locus in cohorts of patients affected with SARS-CoV-2.** Malaspina P, Jodice C, Ciminelli BM, ... Novelli G, Novelletto A. *Hum Genomics*. 2025 Jan 30;19(1):7. doi: 10.1186/s40246-025-00719-8. PMID: 39885568.

2024

9. **Heterozygous BTNL8 variants in individuals with multisystem inflammatory syndrome in children (MIS-C).** Bellos E, Santillo D, Vantourout P, ... Pérez de Diego R, ... Abel L, Zhang SY, Casanova JL, ... Sancho-Shimizu V. *J Exp Med*. 2024 Dec 2;221(12):e20240699. doi: 10.1084/jem.20240699. Epub 2024 Nov 22. PMID: 39576310.
10. **Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease.** Gervais A, Bastard P, Bizien L, ... Abel L, ... Zhang SY, Casanova JL. *J Exp Med*. 2024 Dec 2;221(12):e20240942. doi: 10.1084/jem.20240942. Epub 2024 Nov 1. PMID: 39485284.
11. **Immune response in vaccinated healthcare workers with frequent COVID-19 infections is characterised by blunted IFN γ and IL-2 responses to SARS-CoV-2 variants.** Townsend L, Dunne J, Sui J, ... Reid C, ... O'Farrelly C, ... Conlon N. *Clin Immunol*. 2024 Nov;268:110371. doi: 10.1016/j.clim.2024.110371. Epub 2024 Sep 27. PMID: 39343286.
12. **The Microbe, the Infection Enigma, and the Host.** Casanova JL, Abel L. *Annu Rev Microbiol*. 2024 Nov;78(1):103-124. doi: 10.1146/annurev-micro-092123-022855. Epub 2024 Nov 7. PMID: 38986133.
13. **IL-7-dependent and -independent lineages of IL-7R-dependent human T cells.** Arango-Franco CA, Ogishi M, Unger S, ... Casanova JL, Puel A. *J Clin Invest*. 2024 Oct 1;134(19):e180251. doi: 10.1172/JCI180251. PMID: 39352394.
14. **Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination.** Happle C, Hoffmann M, Kempf A, ... Pöhlmann S, ... Dopfer-Jablonka A. *Lancet Infect Dis*. 2024 Nov;24(11):e674-e676. doi: 10.1016/S1473-3099(24)00603-0. Epub 2024 Sep 25. PMID: 39341219.
15. **Health Care Personnel Workdays Lost and Direct Health Care Salary Costs Incurred due to COVID-19 Infection in the Age of Widespread Vaccine Availability.** Townsend L, Gillespie P, McGrath J, ... Fleming C. *J Infect Dis*. 2024 Oct 16;230(4):e872-e880. doi: 10.1093/infdis/jiae223. PMID: 38771075.
16. **Characterization of the symmetrical benzimidazole twin drug TL1228: the role as viral entry inhibitor for fighting COVID-19.** Murdocca M, Andrade Santos-Filho O, ... Novelli G. *Biol Direct*. 2024 Oct 16;19(1):93. doi: 10.1186/s13062-024-00523-9. PMID: 39415197.
17. **A sensitive assay for measuring whole-blood responses to type I IFNs.** Gervais A, Le Floc'h C, Le Voyer T, ... Zhang SY, ... Bastard P, Casanova JL. *Proc Natl Acad Sci U S A*. 2024 Oct;121(40):e2402983121. doi: 10.1073/pnas.2402983121. Epub 2024 Sep 23. PMID: 39312669.
18. **Inherited human RelB deficiency impairs innate and adaptive immunity to infection.** Le Voyer T, Maglorius Renkilaraj MRL, Moriya K, ... Abel L, ... Casanova JL, ... Puel A. *Proc Natl Acad Sci U S A*. 2024 Sep 10;121(37):e2321794121. doi: 10.1073/pnas.2321794121. Epub 2024 Sep 4. PMID: 39231201.
19. **SARS-CoV-2 brainstem encephalitis in human inherited DBR1 deficiency.** Chan YH, Lundberg V, Le Pen J, ... Abel L, Mogensen TH, ... Casanova JL, ... Zhang SY. *J Exp Med*. 2024 Sep 2;221(9):e20231725. doi: 10.1084/jem.20231725. Epub 2024 Jul 18. PMID: 39023559.
20. **Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection.** Marchal A, Cirulli ET, Neveux I, ... Spaan AN, ... Zhang SY, ... Fellay J, ... Sancho-Shimizu V, Abel L, Casanova JL, ... Bolze A. *HGG Adv*. 2024 Jul 18;5(3):100300. doi: 10.1016/j.xhgg.2024.100300. Epub 2024 Apr 26. PMID: 38678364.
21. **Human determinants of age-dependent patterns of death from infection.** Abel L, Casanova JL. *Immunity*. 2024 Jul 9;57(7):1457-1465. doi: 10.1016/j.immuni.2024.05.020. PMID: 38986441.
22. **Human life within a narrow range: The lethal ups and downs of type I interferons.** Crow YJ, Casanova JL. *Sci Immunol*. 2024 Jul 5;9(97):eadm8185. doi: 10.1126/sciimmunol.adm8185. Epub 2024 Jul 5. PMID: 38968338.

23. **A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern.** Murdocca M, Romeo I, Citro G, ... [Novelli G](#). *Pharmaceuticals (Basel)*. 2024 Jul 4;17(7):891. doi: 10.3390/ph17070891. PMID: 39065742.
24. **Diversification of the VH3-53 immunoglobulin gene segment by somatic hypermutation results in neutralization of SARS-CoV-2 virus variants.** Bruhn M, Obara M, Salam A, ... [Pöhlmann S](#), ... Kalinke U. *Eur J Immunol*. 2024 Jul;54(7):e2451056. doi: 10.1002/eji.202451056. Epub 2024 Apr 9. PMID: 38593351.
25. **Impact of socioeconomic status on healthy immune responses in humans.** Bertrand A, Sugrue J, Lou T, ... [Quintana-Murci L](#), ... [O'Farrelly C](#), ... Milieu Intérieur Consortium. *Immunol Cell Biol*. 2024 Aug;102(7):618-629. doi: 10.1111/imcb.12789. Epub 2024 Jun 11. PMID: 38862267.
26. **Environmental variation and genetic diversity contribute to population differences in immune responses to SARS-CoV-2 and COVID-19 risk.** Rotival M, [Quintana-Murci L](#). *Genes Immun*. 2024 Aug;25(4):338-340. doi: 10.1038/s41435-023-00249-0. Epub 2023 Dec 23. PMID: 38142268.
27. **Variation of the 3'RR1 HS1.2 Enhancer and Its Genomic Context.** Jodice C, Malaspina P, Ciminelli BM, ... [Novelli G](#), [Novelletto A](#). *Genes (Basel)*. 2024 Jun 29;15(7):856. doi: 10.3390/genes15070856. PMID: 39062635.
28. **Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy.** Resa-Infante P, Erkizia I, Muñiz-Trabudua X, ... [Martinez-Picado J](#). *Biomed Pharmacother*. 2024 Jun;175:116726. doi: 10.1016/j.biopha.2024.116726. PMID: 38754263.
29. **The ouroboros of autoimmunity.** Casanova JL, Peel J, Donadieu J, ... [Bastard P](#). *Nat Immunol*. 2024 May;25(5):743-754. doi: 10.1038/s41590-024-01815-y. Epub 2024 May 2. PMID: 38698239.
30. **Human autoantibodies neutralizing type I IFNs: From 1981 to 2023.** [Bastard P](#), Gervais A, Le Voyer T, ... [Abel L](#), [Zhang SY](#), ... [Casanova JL](#). *Immunol Rev*. 2024 Mar;322(1):98-112. doi: 10.1111/imr.13304. Epub 2024 Jan 9. PMID: 38193358.
31. **The immunopathological landscape of human pre-TCR α deficiency: From rare to common variants.** Materna M, Delmonte OM, Bosticardo M, ... [Bastard P](#), ... [Meyts I](#), ... [Abel L](#), ... [Casanova JL](#), [Béziat V](#). *Science*. 2024 Mar;383(6686):eadh4059. doi: 10.1126/science.adh4059. Epub 2024 Mar 1. PMID: 38422122.
32. **Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.** Cossmann A, Hoffmann M, Stankov MV, ... [Pöhlmann S](#), ... [Dopfer-Jablonka A](#). *Lancet Infect Dis*. 2024 Mar;24(3):e145-e146. doi: 10.1016/S1473-3099(23)00783-1. Epub 2024 Jan 8. PMID: 38211602.
33. **Smoking changes adaptive immunity with persistent effects.** Saint-André V, Charbit B, Biton A, ... [Quintana-Murci L](#), ... Milieu Intérieur Consortium. *Nature*. 2024 Feb;626(8000):827-835. doi: 10.1038/s41586-023-06968-8. Epub 2024 Feb 14. PMID: 38355791.
34. **Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.** Stankov MV, Hoffmann M, Gutierrez Jauregui R, ... [Pöhlmann S](#), ... [Behrens GMN](#). *Lancet Infect Dis*. 2024 Jan;24(1):e1-e3. doi: 10.1016/S1473-3099(23)00690-4. Epub 2023 Nov 20. PMID: 37995739.
35. **Memory B cells anticipate SARS-CoV-2 variants through somatic hypermutation.** Bruhn M, Obara M, Chiyyeadu A, ... [Pöhlmann S](#), ... Kalinke U. *J Infect*. 2024 Jan;88(1):57-60. doi: 10.1016/j.jinf.2023.10.020. Epub 2023 Oct 31. PMID: 37913848.
36. **The "Black Swan Principle" and the Genetics of Complex Diseases.** [Novelli G](#), [Reichardt JKV](#). *Top Italian Scientists Journal*; 2024;1(1). <https://doi.org/10.62684/YEWJ9912>.
37. **SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency.** Zhang L, Kempf A, Nehlmeier I, ... [Pöhlmann S](#). *Cell*. 2024 Jan 5:S0092-8674(23)01399-5. doi: 10.1016/j.cell.2023.12.025. Epub ahead of print. PMID: 38194966.
38. **Higher COVID-19 pneumonia risk associated with anti-IFN- α than with anti-IFN- ω auto-Abs in children.** [Bastard P](#), Gervais A, Taniguchi M, ... [Meyts I](#), ... [Zhang SY](#), ... [Mogensen TH](#), ... [Soler-Palacin P](#), ... [Brodin P](#), [Abel L](#), ... [Kisand K](#), ... [Casanova JL](#). *Exp Med*. 2024 Feb 5;221(2):e20231353. doi: 10.1084/jem.20231353. Epub 2024 Jan 4. PMID: 38175961.

2023

39. **Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3.** Zhang L, Kempf A, Nehlmeier I, ... [Pöhlmann S](#), Hoffmann M. *Lancet Infect Dis*. 2023 Oct;23(10):e391-e392. doi: 10.1016/S1473-3099(23)00547-9. Epub 2023 Sep 13. PMID: 37716358.
40. **Dissecting human population variation in single-cell responses to SARS-CoV-2.** Aquino Y, Bisiaux A, Li Z, ... [Abel L](#), [Casanova JL](#), ... [Quintana-Murci L](#). *Nature*. 2023 Aug 9; doi:10.1038/s41586-023-06422-9. PMID: 37558883.
41. **COVID-19 annual update: a narrative review.** Biancolella M, Colona VL, Luzzatto L, ... [Novelli G](#), Reichardt JKV. *Hum Genomics*. 2023 Jul 24;17(1):68. doi: 10.1186/s40246-023-00515-2. PMID: 37488607.
42. **Integrated analysis of whole blood oxylipin and cytokine responses after bacterial, viral, and T cell stimulation reveals new immune networks.** Villain E, Chanson A, Mainka M, ... [Quintana-Murci L](#), ... Milieu Interieur Consortium. *iScience*. 2023 Jul 18;26(8):107422. doi: 10.1016/j.isci.2023.107422. PMID: 37575177.
43. **Immune responses to SARS-CoV-2 infection and vaccination in children.** [Brodin P](#). *Semin Immunol*. 2023 June 20; doi:https://doi.org/10.1016/j.smim.2023.101794.
44. **Omicron subvariant BA.5 efficiently infects lung cells.** Hoffmann M, Wong LR, [Arora P](#), ... [Pöhlmann S](#). *Nat Commun*. 2023 Jun 13;14(1):3500. doi: 10.1038/s41467-023-39147-4. PMID: 37311762.
45. **Polyvalent Nano-Lectin Potently Neutralizes SARS-CoV-2 by Targeting Glycans on the Viral Spike Protein.** Budhadev D, Hooper J, Rocha C, ... [Pöhlmann S](#), Guo Y. *JACS Au*. 2023 Jun 12;3(6):1755-1766. doi: 10.1021/jacsau.3c00163. PMID: 37388683.
46. **Ancient DNA as a tool for medical research.** Kerner G, Choin J, [Quintana-Murci L](#). *Nat Med*. 2023 May; 29(5):1048-1051. doi: 10.1038/s41591-023-02244-4. PMID: 36922577.
47. **Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia.** Su HC, Jing H, Zhang Y, [Casanova JL](#). *Annu Rev Immunol*. 2023; 41:561-585. doi:10.1146/annurev-immunol-101921-050835.
48. **Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia.** Vanker M, Särekannu K, Fekkar A, ... [Zhang SY](#), [Mogensen TH](#), ... [Casanova JL](#), [Kisand K](#). *J Interferon Cytokine Res*. 2023 May 29; doi: 10.1089/jir.2023.0003. Epub ahead of print. PMID: 37253131.
49. **Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia.** Philippot Q, Fekkar A, Gervais A ... [Casanova JL](#), [Puel A](#). *J Clin Immunol*. 2023 May; 20:1–11. doi: 10.1007/s10875-023-01512-9. Epub ahead of print. PMID: 37209324.
50. **Human Genomics of COVID-19 Pneumonia: Contributions of Rare and Common Variants.** Cobat A, Zhang Q, Covid Human Genetic Effort, [Abel L](#), [Casanova JL](#), [Fellay J](#). [published online ahead of print, 2023 May 17]. *Annu Rev Biomed Data Sci*. 10.1146/annurev-biodatasci-020222-021705. doi:10.1146/annurev-biodatasci-020222-021705.
51. **Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage.** Nehlmeier I, Kempf A, [Arora P](#), ... [Pöhlmann S](#), Hoffmann M. *Cell Mol Immunol*. 2023 May; 8:1-3. doi: 10.1038/s41423-023-01030-z. PMID: 37156807.
52. **Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia.** Ana Garcia-Carcia A, [Perez-DeDiego R](#), Flores C, ... [Meyts I](#), ... [Casanova J-L](#), ... et al. *Exp Med*. 2023 May 1; 220(5):e20220170. PMID: 36880831.
53. **PCSK3 Overexpression in Sjögren's Syndrome Patients May Be Regulated by rs4932178 SNP in Its Promoter Region and Correlates with IFN-γ Gene Expression.** Latini A, De Benedittis G, Colafrancesco S, ... [Novelli G](#), ... [Borgiani P](#). *Genes (Basel)*. 2023 Apr 26;14(5):981. doi: 10.3390/genes14050981. PMID: 37239341.
54. **Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5.** Hoffmann M, [Arora P](#), Nehlmeier I, ... [Pöhlmann S](#). *Cell Mol Immunol*. 2023 Apr; 20(4):419-422. doi: 10.1038/s41423-023-00988-0. PMID: 36869193.

55. **Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.** Matuozzo D, Talouarn E, Marchal A ... [Casari G](#) ... [Martinez-Picado J](#) ... [Novelli A](#) ... [de Diego RP](#) ... [Soler-Palacin P](#) ... [Fellay J](#) ... [Mogensen TH](#) ... [Meyts I](#), [Zhang SY](#) ... [Casanova JL](#) ... [Abel L](#), [Cobat A](#). *Genome Med.* 2023 Apr 5; 15(1):22. doi: 10.1186/s13073-023-01173-8. PMID: 37020259.
56. **Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children.** Bucciol G; COVID Human Genetic Effort; [Meyts I](#). *J Allergy Clin Immunol.* 2023 Apr; 151(4):832-840. doi: 10.1016/j.jaci.2023.02.003. Epub 2023 Feb 24. PMID: 36841740.
57. **Human inherited complete STAT2 deficiency underlies inflammatory viral diseases.** Bucciol G, Moens L, Ogishi M, ... [Casanova J-L](#), [Meyts I](#). *J Clin Invest.* 2023 Mar 28:e168321. doi: 10.1172/JCI168321. Online ahead of print. PMID: 36976641.
58. **Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage.** [Arora P](#), [Cossmann A](#), [Schulz SR](#), ... [Pöhlmann S](#), [Hoffmann M](#). *Lancet Infect Dis.* 2023 Feb; 23(2):147-148. doi: 10.1016/S1473-3099(22)00831-3. PMID: 36620969.
59. **Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children.** [Lee D](#), [Le Pen J](#), [Yatim A](#), ... [Meyts I](#), ... [Sancho-Shimizu V](#), ... [Perez de Diego R](#), ... [Abel L](#), ... [Quintana-Murci L](#), ... [Zhang SY](#), [Casanova J-L](#). *Science.* 2023 Feb 10; 379(6632):eabo3627. doi: 10.1126/science.abo3627. Epub 2023 Feb 10. PMID: 36538032.
60. **Omicron sublineage BQ.1.1 resistance to monoclonal antibodies.** [Arora P](#), [Kempf A](#), [Nehlmeier I](#), ... [Pöhlmann S](#), [Hoffmann M](#). *Lancet Infect Dis.* 2023 Jan; 23(1):22-23. doi: 10.1016/S1473-3099(22)00733-2. PMID: 36410372.
61. **Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.** [Sokal A](#), [Bastard P](#), [Chappert P](#) ... [Meyts I](#), ... [Abel L](#), ... [Casanova J-L](#), [Mahévas M](#). *J Exp Med.* 2023 Jan 2; 220(1):e20220258. doi: 10.1084/jem.20220258. Epub 2022 Nov 7. PMID: 36342455.

2022

62. **Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN- α .** [Mathian A](#), [Breillat P](#), [Dorgham K](#), ... [Casanova J-L](#) et al. *Ann Rheum Dis.* 2022 Dec;81(12):1695-1703. doi: 10.1136/ard-2022-222549. Epub 2022 Aug 16. PMID: 35973806.
63. **Lung cell entry, cell-cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75.** [Arora P](#), [Nehlmeier I](#), [Kempf A](#), ... [Pöhlmann S](#), [Hoffmann M](#). *Lancet Infect Dis.* 2022 Nov;22(11):1537-1538. doi: 10.1016/S1473-3099(22)00591-6. PMID: 36116462.
64. **The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant.** [Arora P](#), [Zhang L](#), [Rocha C](#), ... [Pöhlmann S](#), [Hoffmann M](#). *Int J Mol Sci.* 2022 Nov 14;23(22):14057. doi: 10.3390/ijms232214057. PMID: 36430535.
65. **Autoantibodies against type I IFNs in patients with critical influenza pneumonia.** [Zhang Q](#), [Pizzorno A](#), [Miorin L](#), ... [Meyts I](#), ... [Andreacos E](#), ... [Kisand K](#), ... [Abel L](#), ... [Casanova J-L](#). *J Exp Med.* 2022 Nov 7;219(11):e20220514. doi: 10.1084/jem.20220514. Epub 2022 Sep 16. PMID: 36112363.

3 Conclusions

We conclude that the UNDINE project has progressed well, scientifically and educationally, proven by its extensive communication and dissemination activities that have been fostered by the excellent work of the postdoctoral researchers contributing to this success.